Dr Jezabel Garcia Parra
Research Officer
Medicine
Telephone: (01792) 606402
Room: Open Plan Office - 106
First Floor
Institute of Life Science 2
Singleton Campus

Jezabel’s research focuses on the study of novel cancer biomarkers and the development of advanced therapeutics in precision medicine. Her clinical interests are mainly gynaecological (ovarian, endometrial and cervical cancer) and breast cancers. Her scientific career has been always connected to translational medicine and her aim is to contribute improving cancer treatments through preclinical research.

Areas of Expertise

  • Cancer
  • Molecular biology
  • Drug development
  • Biomarker research
  • Reproductive biology

Publications

  1. & Antibody–drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. Interface Focus 6(6), 20160054
  2. & Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer. European Journal of Cancer 50(15), 2725-2734.
  3. & Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Annals of Oncology 23(5), 1156-1164.

Teaching

  • PMNM04 Nanomedicines and Therapeutics

    The module will explore the history and development of molecular medicines. Using landmark technology and chemical development phases, the traditional small chemical entities using in molecular medicine will be outlined, using drugs such as taxols and tamoxifen as exemplars. The common target oncology and non oncology disorders will outlined and their respective targets for such medicines detailed alongside drug modes of action and delivery (IV and oral). Further exploration of targeted nanoparticle delivery, from early first generation drugs such as Abraxane to second generation biologically targeted SMART delivery systems, will expand the knowledge to future molecular medicines such as antibody drug conjugates and kinase inhibitors. Excitingly the module will include guest lectures from industry and clinicians, covering the spectrum of drug development to delivery and clinical considerations.

  • PMNM11 Nanomedicines, pharmaceuticals and advanced therapeutics

    This module will explore the history and development of molecular medicines and pharmaceuticals, providing the basis for an advanced understanding of next generation therapeutic approaches. Using landmark technology and chemical development phases informed by separation science and mass spectrometry, the module uses an application driven approach to provide the student with an extensive knowledgebase of drug development, the pharmaceutical industry and nanotherapeutics. Students will be able to characterize and map the path of a drug from administration, to metabolism and elimination, and critically evaluate drug design and delivery approaches. Traditional small chemical entities used in molecular medicine will be outlined, using drugs such as taxols and tamoxifen as exemplars. Common target oncology and non-oncology disorders will provide the context; with students encouraged to explore targeted nanoparticle fabrication, drug encapsulation and release profiling, from early first generation drugs such as Abraxane to second generation biologically targeted SMART delivery systems. Future molecular medicines such as antibody drug conjugates and kinase inhibitors will be taught by guest lectures from industry and clinicians, covering the spectrum of drug development to delivery and clinical considerations.

Research Groups

  • Reproductive Biology and Gynaecological Oncology

    Reproductive biology and gynaecological oncology research in Swansea covers basic and translational research into: Uterine pathologies, Gynaecological and in vitro fertilisation

Career History

Start Date End Date Position Held Location
2014 Present Researcher Reproductive Biology and Gynecological Oncoloy Research Group, Swansea University Medical School
2006 2012 Research Assistant and PhD Student Barcelona Biomedical Research Park

Key Grants and Projects

  • SMARTExpertise 2018 - 2020

    RISE: ReNeuron, IgInnovations and Swansea University development of Exosomes towards clinical utility

  • Life Science Bridging Fund, AgorIP 2014

    SNIPER ADC development for gynaecological cancers

  • Life Science Research Network Wales 2017 - 2018

    ADC targets from in-silico high-throughput screening identification into target validation